Because of its precedence in phylogeny and its freedom from the requirement for an adaptive immune response (i.e., specific antibody), the alternative pathway for complement activation must be an important mechanism for host defense. Similarly, the prevalence of cells bearing high-affinity receptors for fragments of complement proteins and the effects of complement-receptor interactions which have already been discovered make clear the biologic importance of these receptors. This is a request for continued support to study the interactions between plasma proteins of the complement or properdin system and cells. Two parallel lines of investigation will be pursued. In the first, cells (or particles simulating cells) will be used as targets in model systems to elucidate the mechanisms leading to activation of the alternative (properdin) pathway. The capacity of properdin to discriminate among activators or non-activators will be examined in studies of the kinetics and stoichiometry of binding or purified native or activated properdin in various microenvironments. Antibody immunoglobulins, either murine monoclonals specific for defined antigens on particles, or polyclonal monomeric and polymeric IgA specific for blood group antigens, will be examined for differential effects on classic and alternative pathway activation, and then on interaction of the six alternative pathway factors with defined surfaces. In the second line of investigation the biologic consequences of interactions between activated complement proteins or fragments and their corresponding cell surface receptors will be examined. Using monoclonal antibodies specific for CR1(C3b), CR2(C3d), CR3(iC3b), or Fc receptors and bispecific hybrids of such monoclonals, receptors on human polymophonuclear neutrophils or rat mast cells will be cross-linked and effects on receptor display, endocytosis, oxidative metabolism, enzyme secretion and phagocytosis examined. The receptor on mast cells that is specific for C3a will be studied in terms of binding characteristics and biologic function.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI013049-15
Application #
3125364
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1976-05-01
Project End
1991-09-30
Budget Start
1990-05-01
Budget End
1991-09-30
Support Year
15
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Whiteman, L Y; Purkall, D B; Ruddy, S (1995) Covalent linkage of C3 to properdin during complement activation. Eur J Immunol 25:1481-4
Whiteman, L Y; Purkall, D B; Ruddy, S (1991) Association of activated properdin with complexes of properdin with C3. J Immunol 147:1344-51
Gervasoni Jr, J E; Ruddy, S (1989) Binding of human C3a and the synthetic nonapeptide C3a (tyr-70-77) to rat peritoneal mast cells. Prog Clin Biol Res 297:221-31;discussion 231-2
Willis, H E; Browder, B; Feister, A J et al. (1988) Monoclonal antibody to human IgG Fc receptors. Cross-linking of receptors induces lysosomal enzyme release and superoxide generation by neutrophils. J Immunol 140:234-9
Feister, A J; Browder, B; Willis, H E et al. (1988) Pertussis toxin inhibits human neutrophil responses mediated by the 42-kilodalton IgG Fc receptor. J Immunol 141:228-33
Moxley, G; Ruddy, S (1987) Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis Rheum 30:1097-104
Gelfand, E W; Rao, C P; Minta, J O et al. (1987) Inherited deficiency of properdin and C2 in a patient with recurrent bacteremia. Am J Med 82:671-5
Eby, W M; Irby, W R; Irby, J H et al. (1987) Recurrent meningitis with familial C8 deficiency: case report. Va Med 114:91-4
Gervasoni Jr, J E; Conrad, D H; Hugli, T E et al. (1986) Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan. J Immunol 136:285-92